Brand Intelligence Graph
Company Overview
About Mantis Biotech
Mantis Biotech is a YC-backed AI company that builds digital twins of human physiology to synthesize diverse, realistic clinical trial populations. The company addresses one of drug development's most persistent problems: clinical trials consistently underrepresent women, elderly patients, and minorities, producing efficacy data that fails to predict real-world outcomes across populations. Mantis's AI platform generates synthetic patient data that fills these representation gaps.
Business Model & Competitive Advantage
The company emerged from stealth with a $48 million Series A in February 2026 co-led by Andreessen Horowitz's Bio fund and GV (Google Ventures), with a founding team led by CEO Georgia Witchel. The raise validates the thesis that AI-generated synthetic data can unlock clinical development stages that real-world data constraints currently block — including rare disease programs where patient populations are too small for statistically valid trials.
Competitive Landscape 2025–2026
Mantis targets the $2.6 billion average per-drug development cost, a figure dominated by late-stage trial failures that synthetic data simulation could predict earlier. As regulatory agencies warm to synthetic data for trial enrichment, Mantis is positioned at the intersection of AI, computational biology, and FDA regulatory strategy — a technically defensible and commercially timely position.
Key Differentiators
Emerging Innovator
Mantis Biotech is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Vivtex
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historicall
Prime Medicine
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable
Compare Mantis Biotech with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Mantis Biotech? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Mantis Biotech Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Mantis Biotech vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →